Bevin 135mg Injection

Introduction

Bevin is a medication that contains the active ingredient Mebeverine. It is available in injection form and is used to treat certain gastrointestinal disorders.

Uses

Bevin is prescribed for the treatment of conditions such as irritable bowel syndrome (IBS) and functional gastrointestinal disorders. It helps relieve symptoms like abdominal pain, bloating, and bowel irregularities associated with these conditions.

Dosage and Administration

Bevin should be administered as directed by your healthcare professional. The dosage and frequency of injections will depend on your specific condition and response to treatment. It is typically given by a healthcare provider in a clinical setting.

Mechanism of Action

The active ingredient in Bevin, Mebeverine, works by relaxing the smooth muscles in the gastrointestinal tract. This helps to reduce spasms and relieve symptoms such as abdominal pain and discomfort.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, or dizziness. If any of these side effects persist or worsen, notify your healthcare provider.

Serious side effects are rare but may include allergic reactions such as rash, itching, swelling, severe dizziness, or difficulty breathing. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Bevin may interact with certain medications, including anticholinergic drugs, such as atropine or scopolamine, which may increase the risk of side effects. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before using Bevin, inform your healthcare provider about any allergies you may have, as well as your medical history, including any liver or kidney problems. This medication is not recommended for use during pregnancy or breastfeeding without consulting your healthcare provider.

Certain precautions should be taken while using Bevin. Follow the recommended dosage and administration instructions provided by your healthcare provider. Inform your healthcare provider about any other medications you are taking to avoid potential interactions. If you experience any unusual or severe symptoms while using Bevin, contact your healthcare provider immediately.

Storage

Bevin should be stored in a cool, dry place, away from direct sunlight and heat. It should be kept out of the reach of children and pets. Do not freeze the medication. Follow any specific storage instructions provided by your healthcare provider or on the product packaging.

Patient Tips

• Follow the recommended dosage and administration instructions provided by your healthcare provider.
• If you miss a dose, contact your healthcare provider for guidance.
• Keep a record of your symptoms and any changes you notice while using Bevin.
• Inform your healthcare provider about any other medications you are taking, including prescription, over-the-counter, and herbal products.
• If you have any concerns or questions about Bevin, do not hesitate to consult your healthcare provider for further information and guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Mebeverine: a medicine to treat muscle spasms (NHS UK) [Accessed 5 Jun. 2024] (online) Available at:
• Aurobeverine MR 200mg modified-release capsules, hard (Health Professionals SmPC) Available at:
• MEBEVERINE HYDROCHLORIDE 135MG TABLETS (Drugs.com) [Accessed 20 Jun. 2024] (online) Available at:
• Medications for IBS (International Foundation for Gastrointestinal Disorders) [Accessed 16 Jun. 2024] (online) Available at:
• Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022 Feb 17;11(4):1044. doi: 10.3390/jcm11041044. [Accessed 19 Jun. 2024] Available at: